Want to see DRUG full AI Analyst Report?
Top Page
Bright Minds Biosciences
(NASDAQ:DRUG)
Select Model
Select Model
Rating:45Neutral
Price Target:
$51.00
▼(-35.84% Downside)
Action:Reiterated
Date:10/08/26
Overall score reflects heavy financial drag from no revenue, widening losses, and accelerating cash burn, partially offset by a very low-debt balance sheet and strengthened equity base. Technicals further weigh on the score with the stock trading below all key moving averages and negative MACD alongside very weak momentum. Valuation is constrained by negative earnings and no dividend yield.
Positive Factors
Very low leverage
Extremely low debt reduces refinancing pressure and fixed financial obligations while preserving flexibility to direct capital toward research and development. This gives Bright Minds a less leveraged balance sheet than many development-stage companies, although it does not eliminate the need to fund ongoing losses.
Negative Factors
No operating revenue
With no reported product revenue, Bright Minds lacks an operating base to fund research, clinical trials, or corporate costs internally. The business therefore remains dependent on financing or future partnering and commercialization success, making execution and access to capital central to its medium-term outlook.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Extremely low debt reduces refinancing pressure and fixed financial obligations while preserving flexibility to direct capital toward research and development. This gives Bright Minds a less leveraged balance sheet than many development-stage companies, although it does not eliminate the need to fund ongoing losses.
Read all positive factors
Bright Minds Biosciences (DRUG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$517.67M
Dividend YieldN/A
Average Volume (3M)137.37K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue GrowthN/A
EPS Growth-120.28%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.76
Shares Outstanding9,864,061
10 Day Avg. Volume148,504
30 Day Avg. Volume137,371
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.08
Price to Sales (P/S)0.00
P/FCF Ratio-66.82
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.80K
Enterprise Value/Ebitda-13.94
Forecast
1Y Price Target
$165.25Price Target Upside107.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.5
Revenue Forecast (FY)$25.45M
Bright Minds Biosciences Business Overview & Revenue Model
Company Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for ep...
How the Company Makes Money
Bright Minds Biosciences does not have publicly known recurring revenue from marketed products; therefore, revenue from product sales is null. As a clinical-stage biotech, the company’s ability to generate cash has primarily been tied to financing...
Bright Minds Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Dec 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -40.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -33.94M | -12.15M | -2.73M | -7.30M | -14.96M | -27.64K |
| Net Income | -24.75M | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
Balance Sheet | ||||||
| Total Assets | 310.84M | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M |
| Cash, Cash Equivalents and Short-Term Investments | 308.33M | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Total Debt | 65.70K | 125.78K | 118.96K | 73.55K | 139.91K | 0.00 |
| Total Liabilities | 2.55M | 2.38M | 568.26K | 280.86K | 1.54M | 638.57K |
| Stockholders Equity | 308.30M | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M |
Cash Flow | ||||||
| Free Cash Flow | -25.00M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Operating Cash Flow | -25.00M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 277.00M | 85.57M | 810.57K | 2.19M | 5.20M | 26.06M |
Bright Minds Biosciences Technical Analysis
Negative
79.49
Price Trends
61.80
Negative
66.38
Negative
74.13
Negative
Market Momentum
-2.12
Negative
44.92
Neutral
26.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRUG, the sentiment is Negative. The current price of 79.49 is above the 20-day moving average (MA) of 51.67, above the 50-day MA of 61.80, and above the 200-day MA of 74.13, indicating a neutral trend. The MACD of -2.12 indicates Negative momentum. The RSI at 44.92 is Neutral, neither overbought nor oversold. The STOCH value of 26.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DRUG.
Bright Minds Biosciences Risk Analysis
Bright Minds Biosciences disclosed 26 risk factors in its most recent earnings report. Bright Minds Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bright Minds Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
DRUG
Bright Minds Biosciences
52.48
-6.30
-10.72%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:IBO
Universal Ibogaine Inc
0.01
0.00
0.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.13
-1.88
-93.75%
Bright Minds Biosciences Corporate Events
Bright Minds Biosciences Shareholders Back Board and Auditor at March 2026 AGM
Oct 2, 2026
Bright Minds Biosciences reported the voting results from its annual general meeting of shareholders held on March 31, 2026, where 7,877,637 common shares were cast, representing 80.49% of outstanding shares. Shareholders strongly supported the co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.